Stem cell transplant could be ‘game changer’ for MS patients

Written by Sharon Salt

Results from an international trial have demonstrated that hematopoietic stem cell transplantation (HSCT) is an effective and safe treatment for patients with relapsing multiple sclerosis (MS). The MIST trial demonstrated that HSCT can stabilize relapsing MS and improve disability in individuals who were still experiencing relapses while taking other disease-modifying therapies (DMTs). Professor Basil Sharrack (Royal Hallamshire Hospital, Sheffield, UK), who led the UK arm of the trial, explained: “Almost all patients receiving autologous HSCT showed no signs of their disease being active a year on from having the treatment. And more importantly, their level of disability improved significantly.” The...

To view the full article, please register now for access

It's completely free